Kalaris Therapeutics (KLRS) Change in Cash (2019 - 2026)

Kalaris Therapeutics' Change in Cash history runs 8 years deep, the most recent figure standing at -$63.6 million for Q1 2026.

• In Q1 2026, Change in Cash fell 163.74% year-over-year to -$63.6 million; the TTM figure through Mar 2026 stood at -$66.5 million (down 169.14% YoY), while the FY2025 annual figure was $96.9 million, up 6434.25% from the prior year.
• Change in Cash for Q1 2026 stood at -$63.6 million, down from $55.7 million in the prior quarter.
• The five-year high for Change in Cash was $99.8 million in Q1 2025, with the low at -$101.5 million in Q1 2022.
• The 5-year median for Change in Cash is -$4.3 million (2024), against an average of -$4.7 million.
• Peak annual rise in Change in Cash reached 20416.06% in 2025, while the deepest fall reached 1339.03% in 2025.
• Kalaris Therapeutics' Change in Cash stood at -$17.7 million in 2022, then jumped by 68.97% to -$5.5 million in 2023, then jumped by 95.02% to -$274000.0 in 2024, then soared by 20416.06% to $55.7 million in 2025, then plunged by 214.3% to -$63.6 million in 2026.
• Business Quant data shows KLRS's Change in Cash at -$63.6 million in Q1 2026, $55.7 million in Q4 2025, and -$46.0 million in Q3 2025.